View in EDS

Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.

Saved in:
Bibliographic Details
Title: Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.
Authors: Arias-Badia M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Chen P; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Lwin YM; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Srinath A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Lyu A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Fan Z; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Kwek SS; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Luong DN; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Setayesh A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Sakamoto M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Clark M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Lea A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Wolters RM; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Goodearl A; AbbVie Bioresearch Center, Worcester, Massachusetts, USA., Harding FA; AbbVie Redwood City, Redwood City, California, USA., Gorman JV; Research and Development, AbbVie, North Chicago, Illinois, USA., Ritacco W; AbbVie Bioresearch Center, Worcester, Massachusetts, USA., Fong L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
Source: JCI insight [JCI Insight] 2025 Feb 27; Vol. 10 (7). Date of Electronic Publication: 2025 Feb 27.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40014402
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Arias-Badia+M%22">Arias-Badia M</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Chen+P%22">Chen P</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Lwin+YM%22">Lwin YM</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Srinath+A%22">Srinath A</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Lyu+A%22">Lyu A</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.<br /><searchLink fieldCode="AU" term="%22Fan+Z%22">Fan Z</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Kwek+SS%22">Kwek SS</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Luong+DN%22">Luong DN</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Setayesh+A%22">Setayesh A</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Sakamoto+M%22">Sakamoto M</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Clark+M%22">Clark M</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Lea+A%22">Lea A</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Wolters+RM%22">Wolters RM</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Goodearl+A%22">Goodearl A</searchLink>; AbbVie Bioresearch Center, Worcester, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Harding+FA%22">Harding FA</searchLink>; AbbVie Redwood City, Redwood City, California, USA.<br /><searchLink fieldCode="AU" term="%22Gorman+JV%22">Gorman JV</searchLink>; Research and Development, AbbVie, North Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Ritacco+W%22">Ritacco W</searchLink>; AbbVie Bioresearch Center, Worcester, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Fong+L%22">Fong L</searchLink>; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101676073%22">JCI insight</searchLink> [JCI Insight] 2025 Feb 27; Vol. 10 (7). <i>Date of Electronic Publication: </i>2025 Feb 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+for+Clinical+Investigation%22">American Society for Clinical Investigation </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101676073 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2379-3708 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223793708%22">23793708 </searchLink><i>NLM ISO Abbreviation: </i>JCI Insight <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40014402
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1172/jci.insight.187921
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Arias-Badia M
      – PersonEntity:
          Name:
            NameFull: Chen P
      – PersonEntity:
          Name:
            NameFull: Lwin YM
      – PersonEntity:
          Name:
            NameFull: Srinath A
      – PersonEntity:
          Name:
            NameFull: Lyu A
      – PersonEntity:
          Name:
            NameFull: Fan Z
      – PersonEntity:
          Name:
            NameFull: Kwek SS
      – PersonEntity:
          Name:
            NameFull: Luong DN
      – PersonEntity:
          Name:
            NameFull: Setayesh A
      – PersonEntity:
          Name:
            NameFull: Sakamoto M
      – PersonEntity:
          Name:
            NameFull: Clark M
      – PersonEntity:
          Name:
            NameFull: Lea A
      – PersonEntity:
          Name:
            NameFull: Wolters RM
      – PersonEntity:
          Name:
            NameFull: Goodearl A
      – PersonEntity:
          Name:
            NameFull: Harding FA
      – PersonEntity:
          Name:
            NameFull: Gorman JV
      – PersonEntity:
          Name:
            NameFull: Ritacco W
      – PersonEntity:
          Name:
            NameFull: Fong L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 02
              Text: 2025 Feb 27
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2379-3708
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: JCI insight
              Type: main
ResultId 1